Literature DB >> 9621062

In vivo protein binding and functional analysis of cis-acting elements in the U3 region of the bovine leukemia virus long terminal repeat.

J Xiao1, G C Buehring.   

Abstract

Bovine leukemia virus (BLV) is a member of the human T-cell leukemia virus (HTLV)/BLV group of retroviruses. These viruses regulate their own transcription by producing Tax, a protein which activates the virus promoter region, the long terminal repeat (LTR). To explore the molecular mechanisms involved in the transactivation, we identified protein binding elements by in vivo footprinting and analyzed their function by site- directed mutagenesis. We used in vivo dimethyl sulfate footprinting by ligation-mediated PCR to detect constitutive in vivo protein-DNA interactions in a BLV-producing cell line, Bat2Cl6. The U3 region and part of the R region of the LTR were footprinted. In addition to the cis-acting elements (three cyclic AMP-responsive elements [CREs] and two AP4 sites) reported by others to be important for Tax-mediated activation of the BLV LTR, we found footprints in regions flanking these elements and in the core promoter region. The importance of these sites for transcriptional activation was studied by site-directed mutagenesis followed by promoter function analysis of the mutants with a chloramphenicol acetyltransferase reporter system. Our data corroborate those of others showing that the CREs are necessary for transactivation of the LTR, and they identify two new functional sites not previously reported by others. We show that the middle region of the BLV U3 contains multiple dual-functioning cis-acting elements which act as either positive or negative regulatory elements depending on the cell type tested. This is the first report of a functional mapping of the cis-acting elements of a virus of the HTLV/BLV group.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621062      PMCID: PMC110404     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA).

Authors:  J V PULVERTAFT
Journal:  Lancet       Date:  1964-02-01       Impact factor: 79.321

2.  CHARACTERISTICS AND MODE OF GROWTH OF TISSUE CULTURE STRAIN (EB1) OF HUMAN LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.

Authors:  M A EPSTEIN; Y M BARR
Journal:  J Natl Cancer Inst       Date:  1965-02       Impact factor: 13.506

3.  A nuclear matrix-specific factor that binds a specific segment of the negative regulatory element (NRE) of HIV-1 LTR and inhibits NF-kappa(B) activity.

Authors:  T Hoover; J Mikovits; D Court; Y L Liu; H F Kung
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

4.  An established R3 mouse mammary tumor cell line; kinetics of mammary tumor virus (MTV) production.

Authors:  E Y Lasfargues; B Kramarsky; N H Sarkar; J C Lasfargues; D H Moore
Journal:  Proc Soc Exp Biol Med       Date:  1972-01

5.  Hormone regulation of bovine leukemia virus via the long terminal repeat.

Authors:  G L Niermann; G C Buehring
Journal:  Virology       Date:  1997-12-22       Impact factor: 3.616

6.  Alterations in blood lymphocyte subpopulations and hematologic values in neonatal calves after administration of a combination of multiple-antigen vaccines.

Authors:  L J Allen; M B Kabbur; J S Cullor; I A Gardner; J L Stott; L W George
Journal:  J Am Vet Med Assoc       Date:  1996-08-01       Impact factor: 1.936

7.  Interaction of bovine leukemia virus transactivator Tax with bZip proteins.

Authors:  I M Boros; F Tie; C Z Giam
Journal:  Virology       Date:  1995-12-01       Impact factor: 3.616

8.  Transcriptional activation by protein-induced DNA bending: evidence for a DNA structural transmission model.

Authors:  B S Parekh; G W Hatfield
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

9.  Identification of an NF-kappa B binding site in the bovine leukemia virus promoter.

Authors:  P A Brooks; J K Nyborg; G L Cockerell
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  A redundant nuclear protein binding site contributes to negative regulation of the mouse mammary tumor virus long terminal repeat.

Authors:  D Bramblett; C L Hsu; M Lozano; K Earnest; C Fabritius; J Dudley
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  15 in total

1.  Suboptimal enhancer sequences are required for efficient bovine leukemia virus propagation in vivo: implications for viral latency.

Authors:  C Merezak; C Pierreux; E Adam; F Lemaigre; G G Rousseau; C Calomme; C Van Lint; D Christophe; P Kerkhofs; A Burny; R Kettmann; L Willems
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Overlapping CRE and E box motifs in the enhancer sequences of the bovine leukemia virus 5' long terminal repeat are critical for basal and acetylation-dependent transcriptional activity of the viral promoter: implications for viral latency.

Authors:  Claire Calomme; Ann Dekoninck; Séverine Nizet; Emmanuelle Adam; Thi Liên-Anh Nguyên; Anne Van Den Broeke; Luc Willems; Richard Kettmann; Arsène Burny; Carine Van Lint
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  The region between amino acids 245 and 265 of the bovine leukemia virus (BLV) tax protein restricts transactivation not only via the BLV enhancer but also via other retrovirus enhancers.

Authors:  S Tajima; Y Aida
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Inhibition of histone deacetylases induces bovine leukemia virus expression in vitro and in vivo.

Authors:  C Merezak; M Reichert; C Van Lint; P Kerkhofs; D Portetelle; L Willems; R Kettmann
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

5.  DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding.

Authors:  Valérie Pierard; Allan Guiguen; Laurence Colin; Gaëlle Wijmeersch; Caroline Vanhulle; Benoît Van Driessche; Ann Dekoninck; Jana Blazkova; Christelle Cardona; Makram Merimi; Valérie Vierendeel; Claire Calomme; Thi Liên-Anh Nguyên; Michèle Nuttinck; Jean-Claude Twizere; Richard Kettmann; Daniel Portetelle; Arsène Burny; Ivan Hirsch; Olivier Rohr; Carine Van Lint
Journal:  J Biol Chem       Date:  2010-04-22       Impact factor: 5.157

6.  Defibrinated bovine plasma inhibits retroviral transcription by blocking p52 activation of the NFkappaB element in the long terminal repeat.

Authors:  Marianne J van den Heuvel; Karen F Copeland; Elizabeth C Cates; Barbara J Jefferson; Robert M Jacobs
Journal:  Can J Vet Res       Date:  2007-04       Impact factor: 1.310

7.  Chromatin disruption in the promoter of bovine leukemia virus during transcriptional activation.

Authors:  Laurence Colin; Ann Dekoninck; Michal Reichert; Miriam Calao; Makram Merimi; Anne Van den Broeke; Valérie Vierendeel; Yvette Cleuter; Arsène Burny; Olivier Rohr; Carine Van Lint
Journal:  Nucleic Acids Res       Date:  2011-09-02       Impact factor: 16.971

8.  A detailed molecular analysis of complete bovine leukemia virus genomes isolated from B-cell lymphosarcomas.

Authors:  Gonzalo Moratorio; Sabrina Fischer; Sergio Bianchi; Lorena Tomé; Gonzalo Rama; Gonzalo Obal; Federico Carrión; Otto Pritsch; Juan Cristina
Journal:  Vet Res       Date:  2013-03-18       Impact factor: 3.683

Review 9.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

10.  Comparison of bovine leukemia virus (BLV) and CMV promoter-driven reporter gene expression in BLV-infected and non-infected cells.

Authors:  Jerome S Harms; Kurt A Eakle; Lillian S Kuo; Robert D Bremel; Gary A Splitter
Journal:  Genet Vaccines Ther       Date:  2004-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.